Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial.
Leroux-Roels I, Davis MG, Steenackers K, Essink B, Vandermeulen C, Fogarty C, Andrews CP, Kerwin E, David MP, Fissette L, Vanden Abeele C, Collete D, de Heusch M, Salaun B, De Schrevel N, Koch J, Verheust C, Dezutter N, Struyf F, Mesaros N, Tica J, Hulstrøm V.
Leroux-Roels I, et al. Among authors: de schrevel n, de heusch m.
J Infect Dis. 2023 Mar 28;227(6):761-772. doi: 10.1093/infdis/jiac327.
J Infect Dis. 2023.
PMID: 35904987
Free PMC article.
Clinical Trial.